Related Experiment Videos
Role of the Gut-Liver-Kidney Axis in Disease Manifestation and Biomarker Alterations
Ryuichi Mashima1, Nobuyuki Ishige2
1Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
Abstract:
Biomarkers with potential for use in clinical diagnosis have been widely studied using biochemical techniques. In particular, endogenous and exogenous metabolites have been targeted in clinical settings. Both types of metabolites are either unmetabolized, metabolized with human enzymes, or metabolized with host-resident bacterial enzymes. In standard clinical chemistry, a specimen must be collected following overnight fasting to minimize the effect of dietary input and the subsequent host and microbial metabolism. Current technology allows the detection of nanomolar concentrations of exogenously derived biomarkers, and these ultra-high sensitivity assays have increased the use of trace amounts of such biomarkers. This narrative review explores how the gut-liver-kidney axis modulates disease manifestation and biomarker accumulations in chronic disorders and inborn errors of metabolism in neonates.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Gut-Brain Axis
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Chronic Kidney Disease II: Clinical Manifestations
Bioavailability: Influencing Factors